From the Guidelines
Recent significant developments in dermatology include the emergence of biologics and JAK inhibitors for treating atopic dermatitis, such as dupilumab, upadacitinib, and abrocitinib, which have shown strong evidence for improving disease control and quality of life 1. These advancements have transformed the field of dermatology by providing targeted therapies with fewer side effects and better outcomes for patients. Some key points to consider include:
- The use of biologics, such as dupilumab, has been shown to be effective in treating atopic dermatitis, with strong recommendations for its use in adults with severe disease 1.
- JAK inhibitors, like upadacitinib and abrocitinib, have also demonstrated significant benefits in treating inflammatory skin conditions, including atopic dermatitis 1.
- Phototherapy and systemic therapies, such as ultraviolet B and oral Janus kinase inhibitors, are also effective options for managing atopic dermatitis, although their use should be determined on a case-by-case basis, taking into account the severity of the disease and the patient's quality of life 1.
- The decision to initiate these advanced therapies should be made using shared decision-making between patients and clinicians, considering the efficacy, safety, and accessibility of the available interventions 1. Overall, these developments have improved the management of atopic dermatitis and other inflammatory skin conditions, providing patients with more effective treatment options and better outcomes.
From the Research
New Developments in Dermatology
Some of the recent developments in dermatology include:
- The use of ustekinumab for the treatment of moderate-to-severe psoriasis, which has shown a favorable balance between efficacy, safety, and tolerability 2
- The potential use of crisaborole, a topical phosphodiesterase-4 (PDE4) inhibitor, for the treatment of psoriasis, with two cases reported of successful treatment 3
- The investigation of ustekinumab for the treatment of moderate-to-severe atopic dermatitis, which has shown clinical and molecular effects, but may require further dosing optimization 4
Biologic Therapies for Psoriasis and Psoriatic Arthritis
- Secukinumab, an interleukin-17A inhibitor, has demonstrated higher efficacy compared to adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis 5
- Crisaborole has been shown to be efficacious and well-tolerated in patients with mild-to-moderate atopic dermatitis and other atopic comorbidities, such as asthma, allergic rhinitis, and food allergies 6
Treatment Options for Atopic Dermatitis
- Ustekinumab has been investigated as a potential treatment option for moderate-to-severe atopic dermatitis, with results showing clinical and molecular effects 4
- Crisaborole has been approved for the treatment of mild-to-moderate atopic dermatitis and has been shown to be effective in patients with other atopic comorbidities 6